Table 3.
Anti-SARS-CoV-2 seroconversion rates and titers in COVID-naïve patients prior to the second (T1) vaccine dose and after 4 weeks (T2) in COVID-naïve patients based on diagnoses and therapies.
| T1 | T2 | |
|---|---|---|
| Rheumatoid arthritis titer | 155 (50–484) p < 0.0001 | 2310 (1230–6375) p = 0.007 |
| seroconverted | 49/61 (80.3%) p = 0.01 | 49/49 (100%) |
| Spondyloarthritis titer | 317 (133–622) p = 0.02 | 4040 (2230–6385) |
| seroconverted | 103/108 (95.3%) | 79/79 (100%) |
| Systemic sclerosis titer | 4 (4–4) p < 0.0001 | 25.6 (8.1–380) p < 0.0001 |
| seroconverted | 2/11 (18.1%) p < 0.0001 | 3/11 (27.2%) p < 0.0001 |
| Systemic lupus erythematosus titer | 77.5 (5.6–464) p = 0.005 | 1320 (498–3100) p = 0.007 |
| seroconverted | 7/11 (58.3%) p = 0.002 | 10/10 (100%) |
| Dermatomyositis titer | 4 (4–4.87) p = 0.001 | 134 (121–178) p = 0.004 |
| seroconverted | 0/3 (0%) p < 0.0001 | 3/3 (100%) |
| Autoimmune hepatitis titer | 323 (75–556) p = 0.04 | 3280 (1300–5340) |
| seroconverted | 23/26 (88.4%) | 19/19 (100%) |
| Mycophenolate mofetil | ||
| overall titer | 4 (4–43.8) p < 0.0001 | 156 (27–353) p < 0.0001 |
| seroconverted | 6/23 (26%) p < 0.0001 | 14/22 (63.6%) p = 0.0004 |
| monotherapy titer | 4 (4–7.12) p < 0.0001 | 121 (13.8–517) p < 0.0001 |
| seroconverted | 3/17 (17.6%) p < 0.0001 | 9/16 (56.2%) p = 0.0001 |
| with glucocorticoids titer | 24.3 (4–81.8) p = 0.001 | 399 (141–1948) |
| seroconverted | 3/6 (50%) | 5/6 (83.3%) |
| Glucocorticoids | ||
| monotherapy titer | 229 (222–235) | 5270 (-) |
| seroconverted | 3/3 (100%) | 1/1 (100%) |
| with other therapies titer | 85 (7.6–222) p < 0.0001 | 1620 (797–6650) p = 0.005 |
| seroconverted | 22/35 (62.8%) p < 0.0001 | 26/27 (96.3%) |
| Methotrexate | ||
| monotherapy titer | 285 (104–663) p = 0.03 vs. MFM | 3160 (2470–6690)p = 0.003 vs. MFM |
| seroconverted | 13/14 (92.8%) | 11/11 (100%) |
| with glucocorticoids titer | 87 (40–638) | 9220 (8500–9640) |
| seroconverted | 3/4 (75%) | 4/4 (100%) |
| Azathioprine | ||
| monotherapy titer | 492 (240–825) p < 0.0001 vs. MFM | 3280 (1735–5960) p = 0.02 vs. MFM |
| seroconverted | 16/16 (100%) | 13/13 (100%) |
| with glucocorticoids titer | 37.8 (20.9–461) p = 0.003, p = 0.03 vs. AZA mono | 1620 (804–6605) |
| seroconverted | 4/7 (57.1%) | 5/5 (100%) |
| Anti-TNFalpha | ||
| monotherapy titer | 382 (177–790) p < 0.0001 vs. MFM | 3405 (1715–5340) p = 0.0002 vs. MFM |
| seroconverted | 66/69 (95.6%) | 54/54 (100%) |
| with glucocorticoid titer | 67.8 (4–326) | 1370 (1320–6659) |
| seroconverted | 2/3 (66.6%) | 3/3 (100%) |
| with methotrexate titer | 231 (89.3–899) | 4130 (1830–6340) |
| seroconverted | 11/13 (84.6%) | 11/11 (100%) |
| Anti-IL17 | ||
| monotherapy titer | 228 (96.9–332) p = 0.02 | 3105 (2485–4850) |
| seroconverted | 15/15 (100%) | 10/10 (100%) |
| Anti-IL6R | ||
| monotherapy titer | 262 (109–1043) | 3700 (2020–5290) |
| seroconverted | 6/6 (100%) | 5/5 (100%) |
| JAK inhibitors | ||
| monotherapy titer | 140 (51–493) p = 0.04 | 3750 (1039–6775) |
| seroconverted | 13/15 (86.6%) | 10/10 (100%) |
| with methotrexate titer | 33.9 (8.2–262.2) p = 0.02 | 512 (-) |
| seroconverted | 2/4 (50%) p = 0.004 | 1/1 (100%) |
Titers are expressed as medians (interquartile ranges) (BAU/mL). The prevalence of seroconversion is expressed in ratios (%). Significant p values (p) are detailed in the table and indicate a comparison with the COVID-matched controls at the same time point; when specified, they indicate a comparison with the COVID-matched patients under mycophenolate therapy (vs. MFM) or azathioprine (vs. AZA).